ライブラリ登録: Guest
Begell Digital Portal Begellデジタルライブラリー 電子書籍 ジャーナル 参考文献と会報 リサーチ集
Critical Reviews™ in Eukaryotic Gene Expression
インパクトファクター: 1.841 5年インパクトファクター: 1.927 SJR: 0.649 SNIP: 0.516 CiteScore™: 1.96

ISSN 印刷: 1045-4403
ISSN オンライン: 2162-6502

Critical Reviews™ in Eukaryotic Gene Expression

DOI: 10.1615/CritRevEukaryotGeneExpr.2019025273
pages 127-139

MicroRNAs as Diagnostic, Prognostic, and Therapeutic Biomarkers in Prostate Cancer

Arad Mobasher Aghdam
School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
Atefeh Amiri
Department of Medical Biotechnology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
Reza Salarinia
Department of Medical Biotechnology and Molecular Sciences, School of Medicine, North Khorasan University of Medical Sciences, Bojnurd, Iran
Aria Masoudifar
Department of Molecular Biotechnology, Cell Science Research Center, Royan Institute for Biotechnology, ACECR, Isfahan, Iran
Faezeh Ghasemi
Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Next to Milad Tower, Tehran, Iran
Hamed Mirzaei
Research Center for Biochemistry and Nutrition in Metabolic Diseases, Kashan University of Medical Sciences, Kashan, Iran

要約

Prostate cancer is the most prevalent nonskin cancer and a major cause of cancer-related deaths worldwide. Prostate-specific antigen (PSA) testing is routinely used for screening and early detection of prostate cancer; however, it does not reduce death from prostate cancer. Moreover, PSA is not specific for prostate cancer and results in high false-positive rates, and it is poorly correlated with cancer stage. Therefore, the need for another diagnostic and prognostic factor in prostate cancer is apparent. MicroRNAs (miRNAs) are small, single-stranded, noncoding RNAs which are involved in modulation of gene expression posttranscriptionally. Multiple lines of evidence indicate that miRNAs play key roles in various physiological events. Deregulation of miRNAs is related to initiation and development of various diseases such as prostate cancer. It has been shown that various miRNAs (miR-34, miR-21, miR-155, miR-221, miR-222, and let-7) exert their effects by targeting a variety of cellular and molecular pathways (c-Myc, EZH2, c-RSC, BCL2L2, E2F6, ZEB, HMGA251, and CCND2) involved in prostate cancer pathogenesis. Hence, it seems that miRNA expression profiles can be seen as potential candidates for prognosis, diagnosis, and treatment of prostate cancer. Here, we summarize various miRNAs as prognostic, diagnostic, and therapeutic biomarkers for prostate cancer therapy.


Articles with similar content:

miRNA: A Diagnostic and Therapeutic Tool for Pancreatic Cancer
Critical Reviews™ in Eukaryotic Gene Expression, Vol.27, 2017, issue 3
Muhammad Imran Qadir, Arooj Faheem
Role of lncRNAs as Novel Biomarkers and Therapeutic Targets in Ovarian Cancer
Critical Reviews™ in Eukaryotic Gene Expression, Vol.27, 2017, issue 2
Lian-wen Zheng, Dan-dan Li, Lu-lu Fu, Feng-ge Wang, Ying Xu, Xue-ying Zhang, Xu Zhou, Ling-yun Li, Shu-xiong Chen, Chun-jin Li
MicroRNAs in Bladder Cancer: Expression Profiles, Biological Functions, Regulation, and Clinical Implications
Critical Reviews™ in Eukaryotic Gene Expression, Vol.24, 2014, issue 1
Zhaoqi Shi, Mingxin Zhang, Junjun She, Qingxia Wei
Molecular Cytogenetics of Prostate Cancer
Critical Reviews™ in Oncogenesis, Vol.7, 1996, issue 3-4
Pasi A. Koivisto
MicroRNAs in Gastric Cancer Metastasis
Critical Reviews™ in Eukaryotic Gene Expression, Vol.24, 2014, issue 1
Zhaoqi Shi, Junjun She, Qingxia Wei